Analysts Estimate Report : What to Look Out for Seelos Therapeutics Stock Forecast, Price & News (NASDAQ:SEEL)

0
104

Earnings results for Seelos Therapeutics Stock Forecast, Price & News (NASDAQ:SEEL)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at -0.11 and remained the same over the past month at -0.11. none raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at -0.44 and remained the same over the past month at -0.44 . none raised and none lowered their forecast.

Analyst Opinion on Seelos Therapeutics Stock Forecast, Price & News (NASDAQ:SEEL)

3 Wall Street analysts have issued ratings and price targets for Seelos Therapeutics in the last 12 months. Their average twelve-month price target is $6.67, predicting that the stock has a possible upside of 560.07%. The high price target for SEEL is $12.00 and the low price target for SEEL is $4.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Seelos Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $6.67, Seelos Therapeutics has a forecasted upside of 560.1% from its current price of $1.01. Seelos Therapeutics has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Seelos Therapeutics Stock Forecast, Price & News (NASDAQ:SEEL)

Seelos Therapeutics does not currently pay a dividend. Seelos Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Seelos Therapeutics Stock Forecast, Price & News (NASDAQ:SEEL)

In the past three months, Seelos Therapeutics insiders have not sold or bought any company stock. Only 7.60% of the stock of Seelos Therapeutics is held by insiders. Only 11.53% of the stock of Seelos Therapeutics is held by institutions.

Earnings and Valuation of Seelos Therapeutics Stock Forecast, Price & News (NASDAQ:SEEL

Earnings for Seelos Therapeutics are expected to decrease in the coming year, from ($0.44) to ($0.47) per share. Seelos Therapeutics has a P/B Ratio of 12.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here